AI Article Synopsis
- Alzheimer's disease (AD) is primarily triggered by the production and accumulation of amyloid β-protein (Aβ), leading to neurodegeneration.
- The progression of Aβ involves its initially soluble form turning into toxic aggregates that damage brain cells.
- To counteract this, researchers developed a peptide (β-aminopyrrolidine containing 12 mer peptide 3) that effectively inhibits Aβ aggregation and decreases its harmful effects on cells.
Article Abstract
Alzheimer's disease (AD) is caused by a series of events initiated by the production and aggregation of the amyloid β-protein (Aβ). In the early stages of the disease, Aβ is released in a soluble form then progressively forms oligomeric, multimeric, and fibrillar aggregates, triggering neurodegeneration. Thus, development of inhibitors that initiate reverse Aβ aggregation is thought to be a logical approach in treating AD. In this context, we developed β-aminopyrrolidine containing 12 mer peptide 3 which is very potent in inhibiting the Aβ aggregation and also reducing Aβ(42)-induced cytotoxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/psc.3386 | DOI Listing |
Publication Analysis
Top Keywords
alzheimer's disease
8
aβ aggregation
8
identification β-aminopyrrolidine
4
β-aminopyrrolidine peptides
4
peptides β-amyloid
4
aggregation
4
β-amyloid aggregation
4
aggregation inhibitors
4
inhibitors alzheimer's
4
disease alzheimer's
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!